ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s stock price rose 7.7% during trading on Wednesday . The stock traded as high as $16.30 and last traded at $16.04. Approximately 59,447 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 113,626 shares. The stock had previously closed at $14.89.
ABIVAX Société Anonyme Stock Performance
The firm's fifty day simple moving average is $13.74.
Hedge Funds Weigh In On ABIVAX Société Anonyme
Several institutional investors and hedge funds have recently modified their holdings of the stock. Blackstone Inc. acquired a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at $25,345,000. Commodore Capital LP bought a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at about $20,277,000. Great Point Partners LLC bought a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at about $16,585,000. Franklin Resources Inc. bought a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at about $13,630,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at about $10,807,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.
About ABIVAX Société Anonyme
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Featured Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
